2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

909. Medical Education and Workforce Development: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Women’s Health, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Genetic Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, CLL, Research, Clinical Research, Patient-Reported Outcomes, Study Population, Human
PAPER

4608 Simulation-based mastery learning (SBML) to improve bone marrow biopsy (BMBx) performance: A SIM-bmbx interval analysis

Max Farber Kelsten, MD, Kathryn McDonnell, PA-C2, Yangruijue Ma, MS3, Ruohui Chen, PhD4, Aparna Kalyan, MBBS5
1 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
2 Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States
3 Northwestern University, Chicago, Illinois, United States
4 Northwestern University, Chicago, Illinois, United States
5 Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States

Background:
BMBx is the gold standard diagnostic test for many pathologies. Bedside BMBx is frequently performed by advanced practice clinicians (APCs) and is required of Hematology-Oncology (HO) fellows by the ACGME. Standard apprenticeship-style procedural instruction promotes variability in practice. SBML standardizes instruction to a mastery performance standard (MPS) and is known to improve skill acquisition, retention, and performance. We developed an SBML curriculum for BMBx and herein report an interval efficacy analysis.

Methods:
We developed a 28-item BMBx procedural checklist based on experience, literature review, and institutional feedback. Eight experts completed a Modified Angoff Method that set the checklist MPS at 27. Maintaining sterile technique was mandatory.

HO fellows, HO APCs, and Internal Medicine residents were invited to participate. At enrollment, participants completed a baseline survey of their experience and confidence in performing BMBx. Eight confidence domains were assessed on a scale from 0-100. Participants with < 3 BMBx performed were considered “novice,” while those with > 3 were “experienced.”

Participants completed a baseline simulated BMBx procedural encounter (B1) with the VATA Bonnie Bone Marrow Biopsy Skills Trainer. Performance was evaluated by investigators in real time via the procedural checklist. Participants not meeting the MPS attended a deliberate practice (DP) session, where they received one-on-one procedural coaching. Participants then repeated the simulation (sim). Those not reaching the MPS repeated DP and sims until the MPS was met. Attainment of the MPS was defined as timepoint M1. At M1, participants rated their confidence in performing BMBx.

The study opened in December 2025. The first 15 sims were co-evaluated for rater consistency. This interval analysis is limited to participants that reached M1 through June 2026. The primary endpoint is the change in sim score from B1 to M1 in the complete cohort. Secondary endpoints are reported descriptively and include score change by experience level and medical degree, the number of sims attempted to reach M1, and the change in confidence scores. DP is not considered a repeat sim attempt. Assessments were completed with paired t-tests or Wilcoxon rank sum tests based on the data distribution. The protocol was exempted by Northwestern University’s IRB.

Results:
Cohort Characteristics
Forty-six participants completed B1, including 23 physicians (14 fellows, 9 residents) and 23 APCs. All 20 novices had performed 0 BMBx. Of the 26 experienced participants, 25 had performed >10 BMBx. B1 mean (SD) and median (range) scores among all enrolled participants were 15.6 (6.5) and 17 (2-28), respectively.

Primary Efficacy Analysis
Through June 2026, 23 participants reached M1 and were included in the analysis. The B1 mean score was 17 (5.6) and median was 17 (6–28). The mean M1 score was 27.6 (0.5). Mean change was 10.5 (5.6) (p<0.001). M1 median was 28 (range 27-28). Two participants achieved M1 at B1, 16 achieved M1 at sim 2, and 5 achieved M1 at sim 3.

Subgroup Analysis
Descriptive subgroup analysis was performed for participants reaching M1. Among novices (n=6), B1 mean was 10.7 (2.9) and median was 11 (6-14). Experienced participant (n=17) B1 mean was 19.3 (4.4) and median was 19 (12-28). Physician (n=14) B1 mean was 15.9 (4.9) and median was 16.5 (6-23). APC (n=9) B1 mean was 18.9 (6.4) and median was 19 (11-28). All subgroups had M1 scores similar to the complete cohort.

Confidence Scores
Descriptive subgroup confidence score analysis was performed for participants reaching M1. Novice B1 confidence scores were lower than experienced participants in all categories. Both novice and experienced participants showed numeric improvement in confidence scores at M1 relative to B1. However, novice confidence remained numerically lower for administering adequate local anesthesia (88 vs 97%), troubleshooting for patient safety (78 vs 94%), troubleshooting to obtain an adequate specimen (75 vs 89%), and performing mid-procedure performance self-assessment (83 vs 93%). There were no notable between-group differences between APC and physician confidence scores.

Conclusions:
In an interval analysis, SBML demonstrates excellent signal for improving BMBx technical performance and proceduralist confidence. Benefit was seen across education and experience levels. Final analysis is pending to confirm these results and assess impact on patient satisfaction.

Max Farber Kelsten, MD: No relevant conflicts of interest to declare.